

# New-generation Jeffamine® D230 core amine, TRIS and carboxyl-terminated PAMAM dendrimers: Synthesis, characterization and the solubility application for a model NSAID drug Ibuprofen

Ali Serol ERTÜRK, Mustafa Ulvi GÜRBÜZ, Metin TÜLÜ

## ABSTRACT

Many therapeutically active drugs are poor water soluble and, therefore, bioavailability of these molecules in the living cells is low and a major problem. In this study, new-generation Jeffamine® D230 core, amine (NH<sub>2</sub>), Tris(hydroxymethyl) aminomethane (TRIS), and carboxyl (COOH) terminated poly(amidoamine) PAMAM dendrimers (PAMAMs) were synthesized. Synthesized new-generation PAMAMs were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, ATR-FTIR, and investigated as solubility enhancer of a sample non-steroidal anti-inflammatory drug (NSAID) Ibuprofen (IBU). The effect of generation size (D2-D4), concentration (0-2.0 mM), and

surface functional group (NH<sub>2</sub>, COOH, TRIS) of the synthesized new-generation PAMAMs on the aqueous solubility of IBU was also investigated. The observed solubility enhancement of IBU was in the order of D4.COOH (18.21 mg/mL) > D3.COOH (13.21 mg/mL) > D4.TRIS (10.30 mg/mL) > D2.COOH (8.55 mg/mL) > D3.TRIS (6.04 mg/mL) > D4.NH<sub>2</sub> (4.56 mg/mL) > D3.NH<sub>2</sub> (3.36 mg/mL) > D2.TRIS (2.42 mg/mL) > D2.NH<sub>2</sub> (1.86 mg/mL). Results showed that synthesized PAMAMs improved the solubility of IBU significantly (30 to 247-fold) with an increasing generation size, and concentration.

**Keywords:** Dendrimers, poly (amidoamine) PAMAM, Jeffamine, drug carrier, NSAID, ibuprofen

Ali Serol Ertürk  
Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy,  
Adıyaman University, 02040, Adıyaman, Turkey

Mustafa Ulvi Gürbüz, Metin Tülü  
Department of Chemistry, Yıldız Technical University, 34210, Istanbul, Turkey

**Corresponding Author:**  
Mustafa Ulvi Gürbüz  
e-mail: mustafaulvig@gmail.com  
Phone No.+90 212 3834223

**Submitted / Gönderilme:** 16.08.2016 **Revised / Düzeltilme:** 20.12.2016  
**Accepted / Kabul:** 23.12.2016

## 1. Introduction

The therapeutic efficacy of a drug in an appropriate dose might decrease due to its inadequate access to the target site of action in the body. To overcome this problem, drug is usually given high doses to the body to show the desired impact. Disappearance of the remedial effectiveness of drug substances stems from the low solubility of drug pharmaceutical ingredients in the aqueous environment of the human body. Results of the studies conducted in medicinal chemistry have shown that water-soluble derivatives of the chemical formulations of drugs can be prepared successfully; however, even small constructional changes in the structure may lead to the dramatic decreases in their efficacy (1).

Drug carriers are defined as any substances incorporating to improve the delivery and the effectiveness of drugs (2). Various drug carrier systems such as liposomes, micelles, nanoparticles, and nanorods are used to perform the desired release of the drugs having weak solubility and therefore, low bioavailability in the body, and to minimize the interaction of the drugs with the healthy tissues (3). Regarding these systems, the main encountered drawbacks

are instability within the body, interaction with the healthy tissues, allowing absorption in the kidneys due to nano sizes, and thus, expelling out the blood circulation (4, 5). To avoid these handicaps, dendrimers can take over as potential drug-delivery systems (6).

Among drug carriers systems, poly(amidoamine) (PAMAM) dendrimers (PAMAMs) take an important role not only with their controllable size, structures, and surface functional groups, but also with the presence of large internal cavities, which serve as hosts for many poor soluble active pharmaceutical ingredients (APIs) (7). Core, repeated branches, and type of surface functional groups of PAMAMs are the main factors besides their generation, concentration, and pH media to improve the solubility of drugs. Due to these properties of PAMAMs, they have great advantages in the solubilization and controlled release of many poor soluble pharmaceuticals such as anticancer, antimalarial, antiviral, antitubercular, antimicrobials, non-steroidal anti-inflammatory (NSAIDs) and anti-hypertensive (8-12).

Over the last decades, although PAMAMs have gained much interest in new applications in pharmaceutical chemistry, there still exists reports about the cytotoxicity and hemolytic toxicity of amine-terminated PAMAMs (PAMAM-NH<sub>2</sub>) (8, 13). To get rid of the mentioned toxicity and gain biocompatibility, surface modification of cationic PAMAM-NH<sub>2</sub> dendrimers with anionic or neutral functional groups have been presented (14, 15). Results of these studies have shown that carboxyl-terminated PAMAMs (PAMAM-COOH), in particular, have been found to be less toxic than cationic PAMAM-NH<sub>2</sub> dendrimers (16). On the other hand, Twyman et al. (17) were synthesized Tris(hydroxymethyl) aminomethane (TRIS) terminated PAMAMs (PAMAM-TRIS) as an alternative to PAMAM-COOH in order to use them as drug-delivery systems. The result of their study has showed that PAMAM-TRIS dendrimers increased the solubility of small hydrophobic acidic drugs. However, commercial unavailability, laborious synthesis with three to four-day reaction times, and tedious purification steps when DMSO used as solvent limited the potential use and investigation of PAMAM-TRIS dendrimers as drug carriers for a wide spectrum of poor soluble drugs. In our recent study (18), we have developed a fast, easy and one-pot microwave-assisted synthesis method for the synthesis of PAMAM-TRIS dendrimers. During synthesis, higher product yields (90-96%) and short reaction times (110-140 min) were observed under mild reaction conditions using methanol as solvent. Therefore, higher opportunity of using of PAMAM-TRIS dendrimers as potential drug-delivery systems for the future

studies and clinical applications has been provided (18). Here, we focus on using neutral PAMAM-TRIS dendrimers as potential drug carriers for NSAIDs by using Ibuprofen (IBU) as a sample model drug, and comparing their solubilization properties with cationic PAMAM-NH<sub>2</sub> and anionic PAMAM-COOH dendrimers.

In the current study, new-generation Jeffamine® D230 (D) core NH<sub>2</sub>, TRIS, and COOH-terminated D2-D4 PAMAMs were synthesized. Synthesized new types of PAMAMs were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, ATR-FTIR, spectroscopic titrations, and investigated solubility enhancer of a sample NSAIDs group member drug IBU. On the basis of this aim, the effect of concentration, generation size (D2-D4), and surface functional group (NH<sub>2</sub>, COOH, TRIS) of Jeffamine® D230 (D) cored PAMAMs on the aqueous solubility of IBU (Fig. 1) was also investigated.

## 2. Materials and methods

### 2.1. Materials and apparatus

Jeffamine® D230 (D), methyl acrylate, EDA, TRIS, methanol, n-butanol, NaOH, CuSO<sub>4</sub> and IBU were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). All other chemicals were of analytical grade and used without further purification. All solutions were prepared by using Milli-Q deionized water (Merk Millipore Corporation, Billerica, Massachusetts, USA). The ATR-FTIR spectra (4000–400 cm<sup>-1</sup>) were recorded with a Bruker spectrometer (Ettlingen, Germany). UV-Vis spectra were recorded with PG TG 70 ((Leicestershire, UK). NMR measurements were performed by using a Bruker 500 MHz spectrometer (Ettlingen, Germany). Synthesis System, model Discover (CEM Corporation, North Carolina, USA) with a continuous microwave power delivery system with operator selectable power output from 0 to 300 W (±30 W) programmable in 1-watt increments, infrared temperature control system programmable from 25 to 250 °C, and 5 to 125 mL vessel capacity was used as microwave reactor. Spectroscopic titrations were carried out automatically by using TitroLine® 7000 ((SI Analytics GmbH, Hattenbergstrabe, Germany)) autotitrator equipped with thermostated titration vessel under nitrogen media.


### 2.2. Synthesis of PAMAMs

Microwave-assisted synthesis of PAMAM-NH<sub>2</sub> (D2.NH<sub>2</sub>-D4.NH<sub>2</sub>) and PAMAM-TRIS (D2.TRIS-D4.TRIS) dendrimers with (D) core, from half generation PAMAM-OCH<sub>3</sub>

dendrimers were performed according to our previous studies (19) and (18), respectively. On the other hand, half generation ester terminated PAMAMs (PAMAM-OCH<sub>3</sub>) (D1.5 OCH<sub>3</sub>-D3.5.OCH<sub>3</sub>) were converted to PAMAM-COOH dendrimers (D2.COOH-D4.COOH) by using the slight modification of the literature procedure (20) and our recent study (13) (Scheme 1). Purity of the synthesized new type of PAMAMs was characterized by ATR-FTIR, <sup>1</sup>H NMR, <sup>13</sup>C NMR and, supported by spectroscopic titrations. Some physico-chemical properties of the synthesized PAMAMs were presented in Table 1.

### 2.2.1. General procedure for the microwave-assisted synthesis PAMAM-NH<sub>2</sub> dendrimers

Jeffamine® D230 (**D**) cored PAMAM-NH<sub>2</sub> dendrimers were synthesized according to our previous study (19), and briefly summarized hereafter. This method involves the alkylation (a) and amidation (b) steps (Scheme 1). In the alkylation steps, a methanolic solution of methyl acrylate (2.5 M eq. per terminal amine) was added over to a stirring methanolic solution of dendrimer core (**D**) Jeffamine® D230 (**D**) or full generation PAMAM-NH<sub>2</sub> dendrimers (**D<sub>n</sub>NH<sub>2</sub>**). After



**Scheme 1.** Synthetic routes for higher generation PAMAM-NH<sub>2</sub>, PAMAM-TRIS and PAMAM-COOH dendrimer synthesis.

stirring the resulting reaction mixture for 24 h at room temperature, excess reagents and solvents were removed under vacuum at 65 °C and purified by means of LPR. The resulting PAMAM-OCH<sub>3</sub> dendrimers (**Dn.5.OCH<sub>3</sub>**) D0.5.OCH<sub>3</sub>-D3.5.OCH<sub>3</sub> were colorless oils and product yields were between 95-98% (Table 2).

#### D0.5. OCH<sub>3</sub>

Yellowish gel (12.22 g, 96%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  1739 (C=O). <sup>1</sup>H-NMR  $\delta\text{H}(500 \text{ MHz}; \text{CDCl}_3)$  2.38 (8H, t, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.75 (8H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 3.25 (4H, m, OCH<sub>2</sub>CH<sub>2</sub>NR<sub>2</sub>), 3.62 (12H, s, COOCH<sub>3</sub>). <sup>13</sup>C-NMR  $\delta\text{C}(125 \text{ MHz}; \text{CDCl}_3)$  173.05 (COOCH<sub>3</sub>), 77.36, 77.10, 76.85 (OCH<sub>2</sub>CH<sub>2</sub>O), 51.36 (COOCH<sub>3</sub>), 46.34 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 34.46 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>).

#### D1.5. OCH<sub>3</sub>

Yellowish gel (16.55 g, 95%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  3331 (NH), 1731 (C=O), 1647 (HNC=O), 1545 (HNC=O). <sup>1</sup>H-NMR  $\delta\text{H}(500 \text{ MHz}; \text{CDCl}_3)$  2.34 (16H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.43 (16H, m,

CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.67 (8H, m, CONHCH<sub>2</sub>CH<sub>2</sub>NR<sub>2</sub>), 3.57 (24H, s, COOCH<sub>3</sub>). <sup>13</sup>C-NMR  $\delta\text{C}(125 \text{ MHz}; \text{CDCl}_3)$  172.90 (COOCH<sub>3</sub>), 172.35 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 51.52 (COOCH<sub>3</sub>), 49.17 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 32.59 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>).

#### D2.5. OCH<sub>3</sub>

Yellowish gel (17.91 g, 96%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  3305 (NH), 1732 (C=O), 1645 (HNC=O), 1538 (HNC=O). <sup>1</sup>H-NMR  $\delta\text{H}(500 \text{ MHz}; \text{CDCl}_3)$  2.28 (32H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.46 (32H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.71 (16H, m, CONHCH<sub>2</sub>CH<sub>2</sub>NR<sub>2</sub>), 3.57 (48H, s, COOCH<sub>3</sub>). <sup>13</sup>C-NMR  $\delta\text{C}(125 \text{ MHz}; \text{CDCl}_3)$  172.95 (COOCH<sub>3</sub>), 172.06 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 51.58 (COOCH<sub>3</sub>), 49.19 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 32.62 (CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>).

#### D3.5. OCH<sub>3</sub>

Yellowish gel (10.72 g, 98%). ATR-FTIR  $\nu_{\max}/\text{cm}^{-1}$  3294 (NH), 1731 (C=O), 1644 (HNC=O), 1537 (HNC=O). <sup>1</sup>H-NMR  $\delta\text{H}(500 \text{ MHz}; \text{CDCl}_3)$  2.29 (64H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.48 (64H, m, CH<sub>2</sub>CH<sub>2</sub>COOCH<sub>3</sub>), 2.70 (32H, m, CONHCH<sub>2</sub>CH<sub>2</sub>NR<sub>2</sub>), 3.61 (96H, s, COOCH<sub>3</sub>).

**Table 1.** Some physico-chemical properties of the synthesized PAMAMs (See also Scheme 1).

Dendrimer	Mw <sup>a</sup> (g/mol)	Number of tertiary amines (NR <sub>2</sub> )	Number of terminal amines (NH <sub>2</sub> )	Number of terminal hydroxyls (OH)	Number of terminal carboxyl (COOH)
<i>NH<sub>2</sub>-terminated</i>					
D2.NH <sub>2</sub>	1600	6	8	-	-
D3.NH <sub>2</sub>	3427	14	16	-	-
D4.NH <sub>2</sub>	7081	30	32	-	-
<i>TRIS-terminated</i>					
D2.TRIS	2088	6	-	24	-
D3.TRIS	4403	14	-	48	-
D4.TRIS	9034	30	-	96	-
<i>Carboxyl-terminated</i>					
D2.COOH	1263	6	-	-	8
D3.COOH	2753	14	-	-	16
D4.COOH	5734	30	-	-	32

<sup>a</sup>Molecular weight

**Table 2.** Preparation of Jeffamine® D230 core ester-terminated PAMAM dendrimers (**Dn.5**).

PAMAM-OCH <sub>3</sub> dendrimers	R-NH <sub>2</sub> g (mmol)	MA g, (mmol)	MeOH (mL)	Time (h)	Yield (%)
D0.5.OCH <sub>3</sub>	5.1 (22.17)	9.54 (110)	30	24	96
D1.5.OCH <sub>3</sub>	8.7 (12.66)	10.90 (126)	30	24	95
D2.5.OCH <sub>3</sub>	10.03 (6.26)	10.79 (125)	30	24	96
D3.5.OCH <sub>3</sub>	6.07 (1.77)	6.09 (70)	30	24	98

$^{13}\text{C}$ -NMR  $\delta\text{C}$ (125 MHz;  $\text{CDCl}_3$ ) 173.02 ( $\text{COOCH}_3$ ), 172.05 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 51.59 ( $\text{COOCH}_3$ ), 49.19 ( $\text{CH}_2\text{CH}_2\text{COOCH}_3$ ), 32.62 ( $\text{CH}_2\text{CH}_2\text{COOCH}_3$ ).

In the amidation steps, a 1-5 mL methanolic solution of ethylenediamine (EDA) involving 10 M eq. of excess EDA per ester branched PAMAM- $\text{OCH}_3$  dendrimers were added to a vigorously stirring methanolic solution of half generation PAMAM- $\text{OCH}_3$  dendrimers (Cn.5). The final mixture was irradiated with microwave (MW) at 250 W for 80 min. Final traces of EDA were removed under vacuum below a bath temperature of 65 °C by the azeotropic mixture of n-butanol three times. The resulting product was purified by using LPR. The final products were full generation PAMAM- $\text{NH}_2$  dendrimers (**Dn.NH<sub>2</sub>**) D1.NH<sub>2</sub>-D4.NH<sub>2</sub>. Product yields were in the range of 90-97% (Table 3).

#### D1.NH<sub>2</sub>

Yellowish gel (11.81 g, 97%). ATR-IR  $\nu_{\text{max}}/\text{cm}^{-1}$  3286 (NH), 1642 (HNC=O), 1553 (HNC=O).  $^1\text{H}$ -NMR  $\delta\text{H}$ (500 MHz;  $\text{DMSO-d}_6$ ) 2.20 (8H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.56 (16H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.80 (8H, s,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 3.04 (8H, t,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 8.09 (4H, s,  $\text{NCH}_2\text{CH}_2\text{CONH}$ ).  $^{13}\text{C}$ -NMR  $\delta\text{C}$ (125 MHz;  $\text{DMSO-d}_6$ ) 171.51 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 74.38, 74.16, 74.05 ( $\text{OCH}_2\text{CH}_2\text{O}$ ), 45.43 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 43.05 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 41.83 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 35.91 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ).

#### D2.NH<sub>2</sub>

Yellowish gel (13.23 g, 90%). ATR-IR  $\nu_{\text{max}}/\text{cm}^{-1}$  3281 (NH), 1644 (HNC=O), 1550 (HNC=O).  $^1\text{H}$ -NMR  $\delta\text{H}$ (500 MHz;  $\text{DMSO-d}_6$ ) 2.21 (16H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.57 (16H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.68 (16H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 3.03 (16H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 8.02 (8H, s,  $\text{NCH}_2\text{CH}_2\text{CONH}$ ).  $^{13}\text{C}$ -NMR  $\delta\text{C}$ (125 MHz;  $\text{DMSO-d}_6$ ) 171.49 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 45.48 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 43.02

( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 41.89 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 35.96 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ).

#### D3.NH<sub>2</sub>

Yellowish gel (13.42 g, 90%). ATR-IR  $\nu_{\text{max}}/\text{cm}^{-1}$  3271 (NH), 1654 (HNC=O), 1566 (HNC=O).  $^1\text{H}$ -NMR  $\delta\text{H}$ (500 MHz;  $\text{D}_2\text{O}$ ) 2.25 (32H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.58 (32H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.64 (32H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 3.13 (32H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ).  $^{13}\text{C}$ -NMR  $\delta\text{C}$ (125 MHz;  $\text{D}_2\text{O}$ ) 171.42 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 45.54 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 43.06 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 41.83 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 35.91 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ).

#### D4.NH<sub>2</sub>

Yellowish gel (4.81 g, 93%). ATR-IR  $\nu_{\text{max}}/\text{cm}^{-1}$  3275 (NH), 1634 (HNC=O), 1548 (HNC=O).  $^1\text{H}$ -NMR  $\delta\text{H}$ (500 MHz;  $\text{D}_2\text{O}$ ) 2.25 (64H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.57 (64H, m,  $\text{CH}_2\text{CH}_2\text{CONH}$ ), 2.64 (64H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 3.12 (64H, m,  $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ).  $^{13}\text{C}$ -NMR  $\delta\text{C}$ (125 MHz;  $\text{D}_2\text{O}$ ) 174.90 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 47.04 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ), 44.38 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 41.22 ( $\text{CONHCH}_2\text{CH}_2\text{NH}_2$ ), 35.87 ( $\text{NCH}_2\text{CH}_2\text{CONH}$ ).

#### 2.2.2. General procedure for the microwave-assisted synthesis of PAMAM-TRIS dendrimers

PAMAM-TRIS dendrimers were prepared according to procedure in our recent study (18), and briefly summarized hereafter. A methanolic solution of PAMAM- $\text{OCH}_3$  dendrimers (**D1.5.OCH<sub>3</sub>**-**D3.5.OCH<sub>3</sub>**) were added to a stirred suspension of TRIS (1.2 M equiv. per terminal ester) and anhydrous  $\text{K}_2\text{CO}_3$  (1.5 M equiv. per terminal ester) in 10–15 mL of MeOH. The following mixture was irradiated at 200 W for 120–130 min by refluxing at a bulk temperature of 70–90 °C. The final reaction mixture was filtered to remove excess solid reagents, and the filtrate collected. Then product

**Table 3.** Preparation of Jeffamine® D230 core amine-terminated PAMAM dendrimers (**Dn.NH<sub>2</sub>**).

PAMAM- $\text{NH}_2$ dendrimers	R- $\text{OCH}_3$ g (mmol)	EDA g (mol)	MeOH <sup>a</sup> (mL)	MW (watt)	Time (min)	Yield (%)
<b>D1.NH<sub>2</sub></b>	10.19 (17.74)	42.65 (0.79)	5.0	200	80	97
<b>D2.NH<sub>2</sub></b>	12.64 (9.19)	44.18 (0.73)	5.0	200	80	90
<b>D3.NH<sub>2</sub></b>	12.68 (4.25)	40.94 (0.68)	5.0	200	80	90
<b>D4.NH<sub>2</sub></b>	4.53 (0.73)	14.09 (0.23)	5.0	200	80	93

was purified with the LPR method. The final methanolic solution of retained product (**Dn.TRIS**) was concentrated under vacuum below a bath temperature of 65 °C. The resulting products were D2.TRIS-D4.TRIS, and yields were in the range of 92–95% (Table 4).

#### D2.TRIS

Opaque oil (1.27 g, 94%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  3272 (COH), 1645 (HNC=O), 1567 (HNC=O), 1395 (O-H). <sup>1</sup>H NMR  $\delta\text{H}$ (500 MHz; D<sub>2</sub>O) 2.57 (16H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 2.72 (16H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 3.67 (48H, s, CH<sub>2</sub>OH). <sup>13</sup>C NMR  $\delta\text{C}$ (125 MHz; D<sub>2</sub>O) 181.12, 174.62, 174.46 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 62.06 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 56.43 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 50.32 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 33.21 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>).

#### D3.TRIS

Opaque oil (1.29 g, 95%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  3288 (COH), 1647 (HNC=O), 1569 (HNC=O), 1396 (O-H). <sup>1</sup>H NMR  $\delta\text{H}$ (500 MHz; D<sub>2</sub>O) 2.58 (32H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 2.79 (32H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 3.73 (96H, s, CH<sub>2</sub>OH). <sup>13</sup>C NMR  $\delta\text{C}$ (125 MHz; D<sub>2</sub>O) 181.01, 174.82, 174.66 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 62.26 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 56.51 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 50.70 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 33.34 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>).

#### D4.TRIS

Opaque oil (1.24 g, 92%). ATR-FTIR  $\nu_{\max}/\text{cm}^{-1}$  3292 (COH), 1649 (HNC=O), 1571 (HNC=O), 1396 (O-H). <sup>1</sup>H NMR  $\delta\text{H}$ (500 MHz; D<sub>2</sub>O) 2.55 (64H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 2.76 (64H, m, CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 3.70 (192H, s, CH<sub>2</sub>OH). <sup>13</sup>C NMR  $\delta\text{C}$ (125 MHz; D<sub>2</sub>O) 181.92, 174.49, 174.23 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 62.53 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 56.94 (CONHCR<sub>2</sub>CH<sub>2</sub>OH), 50.41 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>), 33.15 (CH<sub>2</sub>CH<sub>2</sub>CONHCR<sub>3</sub>).

#### 2.3.3. General procedure for the synthesis of PAMAM-COOH dendrimers

PAMAM-COOH dendrimers were prepared by slight modification of literature procedure (20) and our previous recent study (13). A methanolic solution of ester-terminated half generation PAMAM-OCH<sub>3</sub> (**Dn.OCH<sub>3</sub>**) was mixed with 1.5 M equiv. of NaOH per terminal ester. The final mixture was stirred for 24 h. Excess amount of solvent was removed under vacuum at bath temperature 65 °C. The remaining oil was dissolved in methanol and again evaporated in vacuo. Drying under vacuum resulted in a white powder product. The resulting products were D2.COOH-D4.COOH, and yields were 100% (Table 5).

#### D2.COOH

White solid (0,54 g, 100%). ATR-IR  $\nu_{\max}/\text{cm}^{-1}$  3299 (COOH), 1647 (HNC=O), 1569 (HNC=O), 1402 (O-H). <sup>1</sup>H NMR

**Table 4.** Preparation of Jeffamine® D230 core TRIS-terminated PAMAM dendrimers (**Dn.TRIS**).

PAMAM-TRIS dendrimers	R-OCH <sub>3</sub> g (mmol)	TRIS g (mmol)	K <sub>2</sub> CO <sub>3</sub> g (mmol)	MeOH (mL)	MW (watt)	Time (min)	Yield (%)
<b>D2.TRIS</b>	0.9 (0.65)	0.75 (6.2)	1.1 (7.97)	10.0	200	130	94
<b>D3.TRIS</b>	0.94 (0.31)	0.72 (5.95)	1.02 (7.39)	10.0	200	150	95
<b>D4.TRIS</b>	0.98 (0.15)	0.69 (5.7)	0.99 (7.17)	10.0	200	140	92

**Table 5.** Preparation of Jeffamine® D230 core carboxyl-terminated PAMAM dendrimers (**Dn.COOH**).

PAMAM COOH Dendrimers	R-OCH <sub>3</sub> g (mmol)	NaOH g (mmol)	MeOH (mL)	Time (h)	Yield (%)
<b>D2.COOH</b>	0.64 (0.43)	0.2 (5.15)	5.0	24	100
<b>D3.COOH</b>	0.44 (0.15)	0.14 (3.6)	4.0	24	100
<b>D4.COOH</b>	0.88 (0.14)	0.27 (6.87)	4.0	24	100

$\delta$ H(500 MHz; D<sub>2</sub>O) 2.29 (16H, bm, CH<sub>2</sub>CH<sub>2</sub>COOH), 2.56 (16H, bm, CH<sub>2</sub>CH<sub>2</sub>COOH). <sup>13</sup>C NMR  $\delta$ C(125 MHz; D<sub>2</sub>O) 181.21, 181.06 (COOH), 174.38 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 48.94 (CH<sub>2</sub>CH<sub>2</sub>COOH), 34.03 (CH<sub>2</sub>CH<sub>2</sub>COOH).

### D3.COOH

White solid (0,41 g, 100%). ATR-IR  $\nu_{\max}$ /cm<sup>-1</sup> 3309 (COOH), 1650 (HNC=O), 1573 (HNC=O), 1405 (O-H). <sup>1</sup>H NMR  $\delta$ H(500 MHz; D<sub>2</sub>O) 2.23 (32H, bm, CH<sub>2</sub>CH<sub>2</sub>COOH), 2.59 (32H, m, CH<sub>2</sub>CH<sub>2</sub>COOH). <sup>13</sup>C NMR  $\delta$ C(125 MHz; D<sub>2</sub>O) 181.23, 181.17 (COOH), 174.64 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 48.79 (CH<sub>2</sub>CH<sub>2</sub>COOH), 34.12 (CH<sub>2</sub>CH<sub>2</sub>COOH).

### D4.COOH

White powder (0.8 g, 100%). ATR-FTIR  $\nu_{\max}$ /cm<sup>-1</sup> 3305 (COOH), 1641 (HNC=O), 1566 (HNC=O), 1398 (O-H). <sup>1</sup>H NMR  $\delta$ H(500 MHz; D<sub>2</sub>O) 2.28 (64H, bm, CH<sub>2</sub>CH<sub>2</sub>COOH), 2.68 (64H, bm, CH<sub>2</sub>CH<sub>2</sub>COOH). <sup>13</sup>C NMR  $\delta$ C(125 MHz; D<sub>2</sub>O) 181.01, 180.68 (COOH), 174.68 (NCH<sub>2</sub>CH<sub>2</sub>CONH), 48.86 (CH<sub>2</sub>CH<sub>2</sub>COOH), 33.86 (CH<sub>2</sub>CH<sub>2</sub>COOH).

### 2.3. The spectroscopic titrations of PAMAM-COOH and PAMAM-TRIS dendrimers with Cu<sup>2+</sup> ions

Spectroscopic titrations were conducted on the synthesized PAMAM-TRIS and PAMAM-COOH dendrimers to characterize and show the structural monodispersity or homogeneity by using a PG-70 batch type UV-Vis instrument. UV measurements were conducted within the

wavelength range of 400-900 nm with a 10 mm quartz UV cells. The spectroscopic titrations experiments were carried out according to our previous work (18). In summary, Table 6 presents the concentrations of dendrimer and CuSO<sub>4</sub> solutions used in the spectroscopic titration.

### 2.4. Preparation and characterization of drug-PAMAM dendrimer complexes

#### 2.4.1. Preparation of drug-PAMAM dendrimer complexes

Preparation of IBU-PAMAM dendrimer complexes were performed according to literature procedures (21, 22) and mentioned hereafter briefly. The initial molar ratios of IBU to dendrimer were 1:1. The reaction mixtures were stirred at 250 rpm and 37 °C for 24 h. Then, a rotary evaporator was used to remove methanol. The precipitates were dried under vacuum to remove the methanol completely, followed by the addition of deionized water and stirred for another 2 h to extract out drug-dendrimer complex. This solution then filtered through the 0.45  $\mu$ m and lyophilized to remove the water completely. Resulting drug-dendrimer complex was subjected to ATR-FTIR (4000-600 cm<sup>-1</sup>) and UV-Vis (230-400 nm) analysis.

#### 2.4.2.. UV-Vis characterization

IBU-PAMAM dendrimer complexes were diluted properly with methanol to the final concentration of 10  $\mu$ g/mL. The UV spectra of these complexes were collected between the wavelength ranges of 210-400 nm.  $\lambda_{\max}$  = 221 nm was observed to be the maximum absorption band. Any shift


**Table 6.** Concentrations used to titrate aqueous solutions of TRIS and COOH terminated PAMAMs with Cu<sup>2+</sup> ions.

Type of Dendrimer	Dendrimer conc. (mM)	CuSO <sub>4</sub> conc. (mM)	Increment of CuSO <sub>4</sub> ( $\mu$ L)
D4.TRIS	0.301	66.25	630.00
D4.COOH	0.320	66.25	697.00

**Table 7.** Number of tertiary amine groups on PAMAM-TRIS and PAMAM-COOH dendrimers available for binding with Cu<sup>2+</sup> ions<sup>a</sup>

Type of Dendrimer	<sup>3</sup> N theoretical value	<sup>3</sup> N practical value	% Correlation
D4.TRIS	30	28.55 $\pm$ 0.78	95.16
D4.COOH	30	28.92 $\pm$ 0.69	96.40

<sup>a</sup>Results were calculated from potentiometric titrations for five repeated experiments, and presented as mean  $\pm$  confidence intervals.



**Figure 1.** Molecular structure and some physicochemical properties of IBU:  $\lambda_{\max} = 221$  nm,  $pK_a = 4.85$  Mw = 206.3 g/mol

or suppression in this strong band was assigned to complex formation (21-24).


#### 2.4.3. ATR-FTIR spectral studies

PAMAM-COOH dendrimer, IBU, and IBU-PAMAM drug-dendrimer complexes were subjected to ATR-FTIR. The

FTIR spectra were recorded after 20 scans at  $4\text{ cm}^{-1}$  in a wavenumber range of  $4000\text{-}600\text{ cm}^{-1}$ .

#### 2.5. Solubility tests of drugs

The solubility of drugs was determined by using the rotating bottle technique of Higuchi and Connors (25). 5 mL aqueous solutions of PAMAMs with different generation size (D2-D4), surface functional groups ( $\text{NH}_2$ , COOH, TRIS), and molar concentration (0-2 mM) were prepared. Then, excess amounts of drugs were added to each PAMAM dendrimer solution. The resulting suspensions were shaken at 250 rpm and  $37\text{ }^\circ\text{C}$  for 24 h. Then, the solutions were centrifuged at 6000 rpm for five minutes, and insoluble excess drugs was removed by filtering through  $0.45\text{ }\mu\text{m}$  cellulose acetate filter. The absorbances of the test solutions and PAMAMs were measured by PG T-70 UV-Vis spectrophotometer in the characteristic wavelength ( $\lambda_{\max} = 221$  nm for IBU). Absorbances of PAMAMs were subtracted from drug-dendrimer test solution absorbances. The absorbances were



**Figure 2.** Sample representative ATR-FTIR spectra of D3.NH<sub>2</sub>, D3.5.OCH<sub>3</sub>, D4.COOH D4.TRIS PAMAM dendrimers.


correlated with the calibration curve prepared for drugs and the amount of drugs were determined. Three repeated measurements were conducted.

### 3. Results and discussion

#### 3.1. Characterization of PAMAMs

Conversion of PAMAM-OCH<sub>3</sub> dendrimers to PAMAM-NH<sub>2</sub>, PAMAM-COOH and PAMAM-TRIS dendrimers were followed by ATR-FTIR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectra. In the ATR-FTIR characterization, replacement of amide I (~1640 cm<sup>-1</sup>) and amide II (~1540 cm<sup>-1</sup>) peaks, and disappearance of ~1730 cm<sup>-1</sup> peak originating from the ester functional groups of PAMAM-OCH<sub>3</sub> dendrimers evidenced to the fully conversion of PAMAM-OCH<sub>3</sub> dendrimers to PAMAM-NH<sub>2</sub> dendrimers (Fig.2). Similar observation were obtained for PAMAM-OCH<sub>3</sub> to PAMAM-COOH and PAMAM-TRIS dendrimer conversions. Moreover formation of new band at 3500-3100 cm<sup>-1</sup> was assigned as OH part of carboxylic acid and TRIS, which could readily make H-Bond resulting broadening the spectrum (Fig. 2).

Fig. 3 shows a representative sample NMR monitoring spectra of the conversion of D3.5 to D4. COOH and D4. TRIS dendrimers as an example to PAMAM-OCH<sub>3</sub> to PAMAM-COOH and PAMAM-TRIS dendrimers. Investigation of the Fig. 3 reveals that methyl ester peak of D3.5.OCH<sub>3</sub> at 3.61 ppm cannot be observed in the spectra of D4.COOH and D4.TRIS, and confirms the complete conversion of ester groups to acids (D4.COOH, middle in Fig. 3). In addition, formation of a new singlet peak of D4.TRIS at 3.70 ppm affirms the full modification of the ester functional groups to TRIS (D4.TRIS, top in Fig. 3). On the other hand, the fully disappearance of the methyl ester peak of D3.5 at 51.59 ppm during the synthesis of D4.COOH and D4.TRIS was observed. Instead, a new peak at 56.94 ppm (NHCR<sub>3</sub>) and 62.53 ppm (-CH<sub>2</sub>OH) were appeared at TRIS conversions. This was also an indication of good purity. In addition, the signals at 181.92 from exterior amides (C=O), and 174.23, 174.49 ppm from interior amides (C=O) correspond to TRIS, and the interior amides prove the complete conversion of D3.5 to D4.TRIS. Moreover, formation of the 181.01, 180.68, 174.68 ppm corresponding to acids and interior amides proves the fully conversion of D3.5.OCH<sub>3</sub> to D4.COOH. Thus, <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopy evaluations prove good purity. Similar results were observed in the NMR monitoring of the all conversions from PAMAM-OCH<sub>3</sub> dendrimers to synthesized PAMAM-COOH and PAMAM-TRIS dendrimers.




**Figure 3.** <sup>1</sup>H NMR spectrum monitoring of the conversion of Jeffamine core PAMAMs (D3.5.OCH<sub>3</sub> in CDCl<sub>3</sub>, D4.COOH and D4.TRIS in MeOD).

#### 3.2. Spectroscopic characterization and the determination of the number of tertiary amine groups present in PAMAM-COOH and PAMAM-TRIS dendrimers

#### 3.3. Spectroscopic characterization of IBU-PAMAM dendrimer complexes

Spectroscopic titration experiments were conducted according to our recent study (18) by simply adapting from Crooks et al former studies (26, 27). The results of these studies showed that Cu<sup>2+</sup> ions coordinate with a maximum number of four tertiary amines. In similar, our aim in this study was to show the ideal growth of the synthesized PAMAM dendrimers and monodispersity by calculating the exact number of tertiary amines present at D4.TRIS and D4.COOH with the aid of spectroscopic titrations. After addition of Cu<sup>2+</sup> ions at the specific increments (Table 6) to the dendrimer solutions, a sudden change in color to deep blue was observed. The intensity of this color was dependent on Cu(II)-PAMAM-COOH and Cu(II)-PAMAM-TRIS dendrimers complexes of D4.COOH and D4.TRIS characterized with a broad absorption



**Figure 4.** Absorption spectra of PAMAM-COOH dendrimers at 680 nm (a) D4.COOH (0.320 mM) solution titrated with Cu<sup>2+</sup> (66.25 mM), and (b) spectroscopic titration curve of D4.COOH.

band at  $\lambda_{\max}$  680 nm in UV-Vis spectrophotometer (Fig. 4 and Fig. 5). This band (copper *d-d* transition) is the indication of complexation between Cu(II), and the tertiary amine groups of dendrimers at 1:4 molar ratio and coordination (28). The maximum molar excess of Cu<sup>2+</sup> that can be loaded onto PAMAM-TRIS and PAMAM-COOH dendrimers were determined from absorbance at  $\lambda_{\max}$  680 nm versus Cu<sup>2+</sup>/PAMAM-TRIS and Cu<sup>2+</sup>/PAMAM-COOH dendrimers molar ratio plots (Fig. 4 and Fig. 5).


Table 7 presents the theoretical number of tertiary amines (<sup>3</sup>N) present in PAMAM-TRIS and PAMAM-COOH dendrimers (D4.TRIS and D4.COOH) and the experimental found numbers. The results showed that there exist a good correlation between theoretical and practical number of tertiary amine numbers in PAMAM-TRIS and PAMAM-COOH dendrimers. These results are also evidence for the purity, monodispersity therefore ideal growth of synthesized

PAMAM dendrimers with no such kind of impurity like trailing generations.


### 3.3.1. UV-Vis characterization

Fig. 6 shows the UV-Vis spectra of IBU, PAMAM dendrimer, IBU-PAMAM dendrimer complexes in methanol. The  $\lambda_{\max}$  of

IBU is 221 nm and PAMAMs is  $\sim 280$  nm. The suppression of the 221 nm band in the spectrum of alone and IBU-PAMAM dendrimer complexes indicates that the bonding between among dendrimer-drug molecules could be attributed to non-covalent interactions or entrapping of drug molecules to the cavity of dendrimers (29).



**Figure 5.** Absorption spectra of PAMAM-TRIS dendrimers at 680 nm (a) D4.TRIS (0.301 mM) solution titrated with Cu<sup>2+</sup> (66.25 mM), and (b) spectroscopic titration curve of D4.TRIS.




**Figure 6.** UV-spectra of (1) IBU (10  $\mu\text{g/mL}$ ); (2) IBU-D4. COOH complex (10  $\mu\text{g/mL}$ ); (3) IBU-D4.TRIS complex (10  $\mu\text{g/mL}$ ); (4) IBU-D4.NH<sub>2</sub> complex (10  $\mu\text{g/mL}$ ); (5) D4.TRIS (25  $\mu\text{M}$ ); (6) 25  $\mu\text{M}$  D4.NH<sub>2</sub> (25  $\mu\text{M}$ ); (7) D4.COOH (25  $\mu\text{M}$ ).

### 3.3.2. ATR-FTIR characterization

ATR-FTIR spectra of the IBU, D4.COOH, and IBU-D4. COOH complex were recorded between 4000-600  $\text{cm}^{-1}$ , and presented in Fig. 7. Characteristic bands of IBU were found at 2954 and 2867  $\text{cm}^{-1}$  (C-H stretching); 1704  $\text{cm}^{-1}$  (C=O stretching); 1419 (C-H stretching) and 1230  $\text{cm}^{-1}$  (C-O stretching). The ATR-FTIR spectrum of pure D4.COOH showed about at 3270  $\text{cm}^{-1}$ , 3000-2800  $\text{cm}^{-1}$ , 1645  $\text{cm}^{-1}$ , 1560  $\text{cm}^{-1}$ , 1402  $\text{cm}^{-1}$ , and at 1031  $\text{cm}^{-1}$  corresponding to the vibrations of O-H stretching, C-H stretching, C=O stretching, N-H bending, C-O stretching, and C-O stretch groups, respectively. After complexation of PAMAMs with IBU, spectral shifts were observed for the dendrimer characteristic bands at between 0-15  $\text{cm}^{-1}$  because of the hydrophilic interactions with dendrimer polar groups

### 3.4. Effect of dendrimer concentration and generation on the solubility of IBU

The effect of dendrimer concentration and generation size on the aqueous solubility of IBU was studied by using (D)



**Figure 7.** ATR-FTIR spectra of (1) IBU; (2) IBU-D4.COOH complex, and (3) D4.COOH


core and  $\text{NH}_2$ , TRIS and COOH-terminated PAMAMs, and the results were shown in Fig. 8. Results showed that the solubility of IBU enhanced significantly in the presence of PAMAMs with an increasing generation size (D2-D4) and dendrimer concentration (0-2 mM). From these results, it could be concluded that the encapsulation efficiency of PAMAMs increases especially by the increasing generation size and varying functional groups, which could be attributed to dendrimer trapping the drugs by electrostatic interaction, and encapsulation of the inner cavities of dendrimers (30).

### 3.5. Effect of surface functional group on solubility of IBU

Presence of high density of surface functional groups in the structure of PAMAMs make them attractive for solubility enhancement applications of poor soluble drugs in aqueous media. Inner cavities and surface functionality of PAMAMs are responsible for increased solubility and, therefore, they can be acceptable as suitable drug-delivery systems (13). Up to know, the best reported solubility enhancement for IBU was obtained when EDA cored generation 4 amine-terminated PAMAM dendrimer (7.45 mg/mL) (31) and  $\beta$  CD (~ 0.96 mg/mL) (32) eceptients used. IBU is practically water insoluble (0.08 mg/ml). As shown in Fig. 8, the solubility of IBU was increased significantly in comparison with the before mentioned literature in the presence of D4.COOH (18.21 mg/mL), D3.COOH (13.21 mg/mL), D4.TRIS (10.30 mg/mL), D2.COOH (8.55 mg/mL). The observed solubility enhancement was in the decreasing order of D4.COOH (18.21 mg/mL) > D3.COOH (13.21 mg/mL) > D4.TRIS (10.30 mg/mL) > D2.COOH (8.55 mg/mL) > D3.TRIS (6.04 mg/mL) > D4.NH<sub>2</sub> (4.56 mg/mL) > D3.NH<sub>2</sub> (3.36 mg/mL) > D2.TRIS (2.42 mg/mL) > D2.NH<sub>2</sub> (1.86 mg/mL), and in the ranges of 30 to 247-fold. Overall, results indicated that that the solubility of IBU increased with the increasing generation number of all NH<sub>2</sub>, TRIS, and COOH-terminated PAMAM dendrimers. Water-soluble TRIS and COOH-terminated PAMAM dendrimers synthesized in this study could be potential drug carriers for NSAIDs for the future clinal applications and biological studies by eliminating the disadvantages of amine-terminated PAMAMs without causing any lysis of the living cells.

### Acknowledgement

This research has been supported by Yıldız Technical University Scientific Research Projects Coordination Department. Project Number: 2015-01-02-DOP07.



**Figure 8.** Solubility profiles of IBU in the presence of increasing generation and concentrations of COOH, TRIS, and NH<sub>2</sub>-terminated PAMAMs.

**ÖZ**

Birçok terapötik olarak aktif olan ilaçların sudaki çözünürlüğü zayıf ve bundan dolayı canlı hücrelerde biyoyararlanımları düşük ve büyük bir problem oluşturmaktadır. Bu çalışmada, yeni nesil Jeffamine® D230 çekirdekli amin (NH<sub>2</sub>), Tris(hidroksimetil)aminometan (TRIS) ve karboksil (COOH) sonlu poli(amidoamine) PAMAM dendrimerler (PAMAMs) sentezlendi. Sentezlenen yeni tip PAMAMs'lar <sup>1</sup>H NMR, <sup>13</sup>C NMR, ATR-FTIR kullanılarak karakterize edildi ve örnek bir non-steroidal anti-inflamatuvar ilaç (NSAID) olan Ibuprofen (IBU) için çözünürlük arttırıcı olarak araştırıldı. Sentezlenen yeni nesil PAMAMs'ların, jenerasyon büyüklüğünün (D2-D4),

konsantrasyonun (0-2.0 mM) ve yüzey fonksiyonel gruplarının (NH<sub>2</sub>, COOH, TRIS), IBU'nun çözünürlüğüne olan etkisi ayrıca araştırıldı. IBU'nun gözlemlenen çözünürlük artışı, D4.COOH (18.21 mg/mL) > D3.COOH (13.21 mg/mL) > D4.TRIS (10.30 mg/mL) > D2.COOH (8.55 mg/mL) > D3.TRIS (6.04 mg/mL) > D4.NH<sub>2</sub> (4.56 mg/mL) > D3.NH<sub>2</sub> (3.36 mg/mL) > D2.TRIS (2.42 mg/mL) > D2.NH<sub>2</sub> (1.86 mg/mL) sırasındadır. Sonuçlar gösteriyor ki, sentezlenen PAMAMs'ların jenerasyon büyüklüğü ve konsantrasyonun artmasıyla birlikte IBU'nu çözünürlüğü önemli ölçüde artmıştır (30 ile 247 kat arası).

**Anahtar kelimeler:** Dendrimer, poly(amidoamin) PAMAM, Jeffamin, ilaç taşıyıcı, NSAID, ibuprofen

**References**

1. Beezer AE, King ASH, Martin IK, Mitchel JC, Twyman LJ, Wain CF. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. *Tetrahedron* 2003;59: 3873-80.
2. Carriers D. ReferenceMD Available from: <http://www.reference.md/files/D004/mD004337.html> [10 Dem 2016].
3. Felice B, Prabhakaran MP, Rodríguez AP, Ramakrishna S. Drug delivery vehicles on a nano-engineering perspective. *Mater Sci Eng C* 2014;41: 178-95.
4. Fox ME, Szoka FC, Fréchet MJ. Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture. *Acc Chem Res* 2009;42: 1141-51.
5. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. *J Controlled Release* 2005;102: 23-38.
6. Jia L, Xu J-P, Wang H, Ji J. Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers. *Colloids Surf B* 2011;84: 49-54.
7. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. *J Controlled Release* 2000;65: 133-48.
8. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. *Prog Polym Sci* 2014;39: 268-307.
9. Zhang L, Pornpattananankul D, Hu C-M, Huang C-M. Development of nanoparticles for antimicrobial drug delivery. *Curr Med Chem* 2010;17: 585-94.
10. Gupta U, Agashe HB, Asthana A, Jain N. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. *Biomacromolecules* 2006;7: 649-58.
11. Ly TU, Tran NQ, Hoang TKD, Phan KN, Truong HN, Nguyen CK. Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. *J Biomed Nanotechnol* 2013;9: 213-20.
12. Kumar PD, Kumar PV, anneer Selvam T, Rao KS. Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug. *Res Pharm* 2015;3.
13. Ozturk K, Erturk AS, Sarisozen C, Tulu M, Calis S. Cytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers. *J Microencapsul* 2014;31: 127-36.
14. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. *Int J Pharm* 2003;252: 263-66.
15. Medina SH, El-Sayed ME. Dendrimers as carriers for delivery of chemotherapeutic agents. *Chem Rev* 2009;109: 3141-57.
16. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. *Adv Drug Delivery Rev* 2005;57: 2215-37.
17. Twyman LJ, Beezer AE, Esfand R, Hardy MJ, Mitchell JC. The synthesis of water soluble dendrimers, and their application as possible drug delivery systems. *Tetrahedron Lett* 1999;40: 1743-46.
18. Ertürk AS, Gürbüz MU, Tülü M, Bozdoğan AE. Water-soluble TRIS-terminated PAMAM dendrimers: microwave-assisted synthesis, characterization and Cu (ii) intradendrimer complexes. *RSC Adv* 2015;5: 60581-95.
19. Ertürk AS, Tülü M, Bozdoğan AE, Parali T. Microwave assisted synthesis of Jeffamine cored PAMAM dendrimers. *Eur Polym J* 2014;52: 218-26.
20. Yin R, Zhu Y, Tomalia D, Ibuki H. Architectural copolymers: rod-shaped, cylindrical dendrimers. *J Am Chem Soc* 1998;120: 2678-79.
21. Gürbüz MU, Ertürk AS, Tülü M. Synthesis of surface modified TREN cored PAMAM dendrimers and their effects on the solubility of sulfamethoxazole (SMZ) as an analogue antibiotic drug. *Pharm Dev Technol* 2016: 1-33.
22. Ertürk AS, Gürbüz MU, Tülü M. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil. *Pharm Dev Technol* 2016: 1-34.
23. Kleinman MH, Flory JH, Tomalia DA, Turro NJ. Effect of protonation and PAMAM dendrimer size on the complexation and dynamic mobility of 2-naphthol. *J Phys Chem B* 2000;104: 11472-79.

24. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. *Int J Pharm* 2003;259: 143-60.
25. Higuchi T, Connors KA. Phase-solubility techniques. *Advan Anal Chem Instr* 1965;4: 117-212.
26. Feng ZV, Lyon JL, Croley JS, Crooks RM, Vanden Bout DA, Stevenson KJ. Synthesis and Catalytic Evaluation of Dendrimer-Encapsulated Cu Nanoparticles. An Undergraduate Experiment Exploring Catalytic Nanomaterials. *Journal of Chemical Education* 2009;86: 368.
27. Zhao M, Sun L, Crooks RM. Preparation of Cu Nanoclusters within Dendrimer Templates. *Journal of the American Chemical Society* 1998;120: 4877-78.
28. Chen P, Yang Y, Bhattacharya P, Wang P, Ke PC. A Tris-Dendrimer for Hosting Diverse Chemical Species. *The Journal of Physical Chemistry C* 2011;115: 12789-96.
29. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. *J Drug Target* 2004;12: 575-83.
30. Devarakonda B, Hill R, Devilliers M. The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. *Int J Pharm* 2004;284: 133-40.
31. Yiyun C, Tongwen X. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. *Eur J Med Chem* 2005;40: 1188-92.
32. Chow DD, Karara AH. Characterization, dissolution and bioavailability in rats of ibuprofen- $\beta$ -cyclodextrin complex system. *Int J Pharm* 1986;28: 95-101.